Eli Lilly and Company, Verona Pharma PLC American Depositary Share, and Pfizer are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture and market prescription drugs and therapeutics. Investors in these stocks gain partial ownership in firms whose valuations hinge on drug pipeline progress, regulatory approvals and patent lifecycles. As a result, pharmaceutical equities often exhibit volatility tied to clinical trial outcomes, patent expirations and industry-wide regulatory changes. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of LLY traded down $22.98 during mid-day trading on Tuesday, hitting $776.36. The company's stock had a trading volume of 2,351,439 shares, compared to its average volume of 3,665,612. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The firm has a 50-day moving average price of $765.95 and a 200 day moving average price of $800.18. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The stock has a market capitalization of $735.78 billion, a price-to-earnings ratio of 63.26, a PEG ratio of 1.16 and a beta of 0.40.
Read Our Latest Research Report on LLY
Verona Pharma PLC American Depositary Share (VRNA)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Shares of VRNA traded up $0.16 during trading hours on Tuesday, hitting $104.83. 8,745,274 shares of the company were exchanged, compared to its average volume of 2,243,382. The firm has a fifty day simple moving average of $84.54 and a 200-day simple moving average of $68.38. The company has a market capitalization of $8.92 billion, a PE ratio of -52.41 and a beta of 0.24. The company has a debt-to-equity ratio of 1.07, a current ratio of 8.86 and a quick ratio of 8.73. Verona Pharma PLC American Depositary Share has a one year low of $18.51 and a one year high of $104.99.
Read Our Latest Research Report on VRNA
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
NYSE PFE traded down $0.68 on Tuesday, hitting $24.68. 30,385,219 shares of the company were exchanged, compared to its average volume of 41,744,835. The company's 50 day moving average price is $23.92 and its 200-day moving average price is $24.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The firm has a market capitalization of $140.29 billion, a P/E ratio of 17.89, a price-to-earnings-growth ratio of 0.93 and a beta of 0.58. Pfizer has a twelve month low of $20.92 and a twelve month high of $31.54.
Read Our Latest Research Report on PFE
See Also
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
